Journal Article

Suppression of <i>N-</i>nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor

Zhigang Li, Yutaka Shimada, Atsushi Kawabe, Fumiaki Sato, Masato Maeda, Izumi Komoto, Tao Hong, Yongzeng Ding, Junichi Kaganoi and Masayuki Imamura

in Carcinogenesis

Volume 22, issue 4, pages 547-551
Published in print April 2001 | ISSN: 0143-3334
Published online April 2001 | e-ISSN: 1460-2180 | DOI:
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Recent studies have demonstrated that overexpression of cyclooxygenase-2 (COX-2) and elevation of COX-2-mediated synthesis of prostaglandin E2 (PGE2) were observed in various cancers including esophageal cancer, but their roles in carcinogenesis of the esophagi still remain unclear. To address the issue, we observed the reduction of N-nitrosomethylbenzylamine (NMBA)-induced tumorigenesis in rat esophagi via JTE-522 (4-[4-cyclohexyl-2-methyloxazol-5-yl]-2-fluorobenzenesulfonamide), a selective COX-2 inhibitor. In this study, 54 F344 male rats were divided into nine groups; JTE-522 (3, 9 and 30 mg/kg) was administered orally. We also examined the effects of JTE-522 on COX-2 mRNA and synthesis of PGE2. In the group in which JTE-522 was administered intermittently at a daily dose of 30 mg/kg, the number of NMBA-induced esophageal tumors per rat significantly reduced, to 62% (P < 0.05), but the size of the tumors was not significantly inhibited. In the group in which JTE-522 was administered continuously five times weekly for 24 weeks at a daily dose of 9 mg/kg, both the number and size of tumors significantly reduced, to 29 and 44%, respectively (P < 0.05). Furthermore, JTE-522 suppressed not only tumor formation but also developing carcinomas (P < 0.0001). In this study, treatment with NMBA alone resulted in an ~5-fold rise in expression of COX-2 mRNA detected by semi-quantitative RT–PCR analysis and an ~7-fold increase in the production of PGE2 measured by ELISA compared with the normal esophageal mucosa. The up-regulated COX-2 expression did not decrease with the treatment of JTE-522 at the 3, 9 and 30 mg/kg doses; however, the increased levels of PGE2 synthesis were significantly decreased by administering JTE-522 (P < 0.01). Our study suggests that COX-2-mediated PGE2 is important in NMBA-induced esophageal tumorigenesis in rats, and therefore may be a promising chemotherapeutic target for the prevention and treatment of esophageal cancer, especially with selective COX-2 inhibitors.

Keywords: CMC-Na, carboxymethyl celluose sodium; COX, cyclooxygenase; JTE-522, 4-[4-cyclohexyl-2-methyloxazol-5-yl]-2-fluorobenzenesulfonamide; NSAIDs, non-steroidal anti-inflammatory drugs; NMBA, N-nitrosomethylbenzylamine; PGE2, prostaglandin E2.

Journal Article.  4428 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.